Buonfrate D, Salas-Coronas J, Muñoz J, et al. - Researchers designed a multicentre, open-label, phase 3, randomized controlled superiority trial investigating the efficacy of multiple doses of ivermectin vs single dose for the treatment of non-disseminated strongyloidiasis. In four centers in Italy, three in Spain, and two in the UK, 309 eligible patients were randomized to receive either one dose (n = 155) or four doses (n = 154) of ivermectin. Outcomes revealed no higher efficacy of multiple doses of ivermectin and further, these were less tolerated than a single dose. Hence they prefer using a single dose for the treatment of non-disseminated strongyloidiasis.